Business
Cannabics Pharmaceuticals Granted Patent in South Africa for Its Personalized Cannabinoid Based Diagnostics
Cannabics Pharmaceuticals Granted Patent in South Africa for Its Personalized Cannabinoid Based Diagnostics.
About this update from Cnbx Pharmaceuticals Inc.
[{"type":"text","content":"\n\n\n\nCannabics Pharmaceuticals Granted Patent in South Africa for Its Personalized Cannabinoid Based Diagnostics\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nCannabics Pharmaceuticals Granted Patent in South Africa for Its Personalized Cannabinoid Based Diagnostics\nPR Newswire\nTEL AVIV, Israel and BETHESDA, Maryland, Oct. 25, 2018\n\n\n\nTEL AVIV, Israel and BETHESDA, Maryland, Oct. 25, 2018 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced today that it has been granted its patent for its core technology by the South Africa Patent Office. Following the patent's approval in Israel in September 2018, this patent encompasses the systems and methods required to produce data on the interaction between different cannabinoids and cancer cells. This technology enables screening the effects of a multitude of compounds derived from the cannabis plant on cancer cell lines and biopsies. The technology will facilitate the development of more accurate cannabinoid compounds designated for specific cancers and specific genetic profile of patients, and at the same time will serve as a source for supportive data for cannabinoid-based treatments.  \n\n \n \n\n \n\"In South Africa, a recent ruling by the constitutional court made it legal for adults to cultivate and use cannabis in private in their homes, paving the way for better access to cannabinoid compositions,\" said Dr. Eyal Ballan, Cannabics co-founder and chief technology officer. \nAbout Cannabics Pharmaceuticals  \nCannabics Pharmaceuticals Inc. (CNBX) is a U.S public company that is developing a platform which leverages novel drug-screening tools and artificial intelligence to create cannabinoid-based therapies for cancer that are more precise to a patient's profile. By developing tools to assess effectiveness on a personalized basis, Cannabics is helping to move cannabinoids into the future of cancer therapy. The company's R&D is based in Israel, where it is licensed by the Ministry o...